Press Releases April 28, 2026 04:15 PM

Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026

Bioventus announces Q1 fiscal 2026 earnings release and conference call scheduled for May 6, 2026.

By Marcus Reed BVS
Bioventus to Report First Quarter of Fiscal Year 2026 Financial Results on May 6, 2026
BVS

Bioventus Inc., a leader in active healing innovations, will report its first quarter fiscal year 2026 financial results on May 6, 2026, before market open. The company will host a conference call to discuss these results and provide a business update.

Key Points

  • Bioventus is scheduled to report Q1 fiscal 2026 financial results on May 6, 2026.
  • The company will hold a conference call for investors and media on the day of the earnings release.
  • Bioventus focuses on products for pain treatment, restorative therapies, and surgical solutions, impacting healthcare and medical device sectors.

DURHAM, N.C., April 28, 2026 (GLOBE NEWSWIRE) -- Bioventus Inc. (Nasdaq: BVS) (“Bioventus” or the “Company”), a global leader in innovations for active healing, today announced that it will report financial results for the first quarter of fiscal year 2026 before the market opens on Wednesday, May 6, 2026. The Company’s management will host a conference call at 8:30 a.m. Eastern Time that same day to discuss the results and provide a business update.

To participate in the conference call, dial 1-833-636-0497 and refer to the Bioventus Inc. Conference Call.

A live webcast of the call and accompanying materials will also be provided on the “Investor Relations” section of the Company's website at https://ir.bioventus.com/. The webcast will be archived at the same site and available for replay until May 5, 2027.

About Bioventus
Bioventus delivers clinically proven, cost-effective products that help people heal quickly and safely. Its mission is to make a difference by helping patients resume and enjoy active lives. The Innovations for Active Healing from Bioventus include offerings for Pain Treatments, Restorative Therapies and Surgical Solutions. Built on a commitment to high quality standards, evidence-based medicine and strong ethical behavior, Bioventus is a trusted partner for physicians worldwide. For more information, visit www.bioventus.com and follow the Company on LinkedIn and X. Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC.

Investor and Media Inquiries:
Dave Crawford
919-474-6787
[email protected]  


Risks

  • Financial performance remains unknown until the report is released, creating possible uncertainty.
  • Market reaction depends on earnings results and management commentary during the conference call.
  • Competitive pressures in the medical products and active healing sectors could impact future results.

More from Press Releases

Fiverr Announces First Quarter 2026 Results Apr 29, 2026 Nayax to Report 2026 Q1 Earnings on May 12, 2026 Apr 28, 2026 Xunlei Filed Its Annual Report on Form 20-F for Fiscal Year 2025 Apr 28, 2026 Mesoblast Achieves Patient Recruitment Target in Pivotal Phase 3 Trial for Chronic Low Back Pain Apr 28, 2026 Syntec Optics (Nasdaq: OPTX) Announces Pricing of $20 Million Underwritten Public Offering of Common Stock Apr 28, 2026